Developing new treatments targeting a virus linked to cancer
Structural analysis and therapeutic nanobody development of KSHV G-protein coupled receptor
['FUNDING_R01'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10849739
This study is looking at a virus linked to cancer and aims to develop new treatments that can block a specific protein from the virus that helps it cause disease, which could benefit people dealing with KSHV-related health issues.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10849739 on ClinicalTrials.gov |
What this research studies
This research focuses on the Kaposi’s sarcoma-associated Herpesvirus (KSHV) and its role in cancer development. The team aims to analyze a specific viral protein that mimics a human receptor involved in cell signaling, which is crucial for many biological processes. By using biochemical techniques and signaling assays, they plan to create therapeutic nanobodies that can inhibit the cancer-causing effects of this viral protein. This approach could lead to new treatments for patients affected by KSHV-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with KSHV-related cancers or those at high risk of developing such conditions.
Not a fit: Patients with cancers unrelated to KSHV or those who do not have a KSHV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide targeted therapies for patients suffering from cancers associated with KSHV infection.
How similar studies have performed: Previous research has shown promise in targeting GPCRs for therapeutic interventions, indicating a potential for success in this novel approach.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JUNG, JAE U — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: JUNG, JAE U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer